Increase measurement accuracy

Voxcan uses non-invasive high-resolution imaging (in vivo bioluminescence, fluorescence, CT, micro-CT) to generate optimal quantification of your preferred study endpoints. Non-invasive imaging minimizes the risk of bias due to intra-strain variability, tissue alterations and operator-dependent errors. This gives you greater confidence in biological results and therefore a better understanding of the mechanism of action of your therapy.

Save animals

Longitudinal monitoring of disease progression and compound biodistribution is possible thanks to non-invasive in vivo imaging (bioluminescence, fluorescence imaging, CT, micro-CT). Compared to conventional terminal endpoints (histology, ex vivo analysis), non-invasive monitoring reduces the number of animals needed for preclinical studies by up to 80% and at the same time refines procedures, fully committing to the 3Rs and high ethical standards.

Save time

Thanks to non-invasive in vivo imaging, preclinical studies can be completed up to 5 times faster than conventional studies using intermediary terminal endpoints. By saving time on preclinical studies, this gives you the opportunity to concentrate on planning the next stages of your product development and to reduce time-to-market.

Save money

By using less animals and obtaining study endpoints faster, our non-invasive high-technology approach reduces costs for your preclinical testing. This translates into financial savings and gives you greater flexibility for the next stages of product development.

Translational research

Preclinical non-invasive imaging on small to large animals uses similar technology in terms of hardware, software and image analysis as used for human patients. Therefore, our imaging services provide preclinical results that are more readily translatable to human studies.